Participants were recalled for a fresh blood sample, and testing included the RSA, 3rd generation Ortho Anti-HCV Ab EIA, ADVIA Centaur HCV chemiluminiscent immunoassay (CIA) assay, quantitative viral load and genotyping. RESULTS: Of the 363 subjects studied, 87 were confirmed as positive cases with both a positive RSA and CIA result with a signal / cut-off (S/C) ratio of ≥11 per prior guidelines. The CIA, implementing the S/C ratio, was excellent at diagnosing active (detectable viremia) infection, with a sensitivity

of 93.0% and specificity of 95.3%. Depending on the S/C ratio used for the CIA, the rate of active infection ranged from 74.4%-88% in those identified as seropositive. The RSA, however, had the best sensitivity for detecting Selleck Carfilzomib active infection, at 98.6%; however the rate of false positives was higher, with a positive predictive value for

active infection of only 42.2%. The mean viral load was 5.6 log IU / ml, and ALT and AST values were elevated in actively infected cases. All samples were classified as genotype 1 or 2, but displayed high levels of intra and inter patient viral diversity. CONCLUSIONS: These results illustrate a high rate of active (viremic) infection in true seropositive individuals, contrary to prior reports. Actively infected individuals also had elevated liver transaminases and high circulating viral loads. Appropriate testing strategies in SSA will help to identify the true disease burden in SSA, and help guide screening practices. Disclosures: The following Angiogenesis inhibitor people have nothing to disclose: Jennifer E. Layden, Richard O. Phillips, Fred S. Sarfo, Nallely Mora, Dorcas O. Owusu, Stephanie Kliethermes, Shirley P. Owusu-Ofori, Joseph Forbi, Ohene Opare-Sem, Kenrad Nelson, Richard

Cooper Background and aims Staging fibrosis is crucial in patients with chronic hepatitis C (CHC) patients because it reflects the progression of the disease and it is often taking into account in the decision to treat. MiRNAs regulate the expression of up to 60% of mRNAs. MiR-122 is highly expressed in the liver and regulates HCV replication. MiRNAs are stable compared mafosfamide to mRNAs and therefore are increasingly investigated as bio-markers. We aimed to identify miRNAs differentially expressed during fibrosis in patients with chronic hepatitis C. Patients and Methods Serum samples and liver biopsies were available for respectively 86 and 40 patients. Among patients with available serum samples, the mean viral load was 1300 UI/ mLx103. HCV-G1 (61%), and G4 (18,6%) were the most represented. Fibrosis distribution was F1 (31,4%), F2 (20,9%), F3 (23,3%) and F4 (24,4%). Among patients with available biopsies, the mean viral load was 820 UI/ mLx103, genotype distribution was HCV-G1 (50%), G2 (7,5%), G3 (17,5%), G4 (25%) and fibrosis distribution was F1 (27,5%), F2 (17,5%), F3 (27,5%) and F4 (27,5%). Fibrosis was staged according to the Metavir score system (F0 to F4).